Table 1

Studies of the extended HR-HPV genotyping on risk stratification for cervical cancer and precursors.

Reference

Country

Research design

Cases

Results

Follow-up

31

Sweden

prospective nested case-control

1226

The risk of cervical squamous cell carcinoma tripled within 7 years in patients who initially tested positive for non-16/18 HR-HPV than that for the HPV negative women.

7 years

32

Sweden

prospective multicenter study

5696

HPV-31 and HPV-33 positive women had a higher risk of CIN2+ than HPV-18 positive women.

4.1 years

33

USA

prospective multicenter study

27,037

HPV-16 and 31 have the highest risk of CIN2+ and CIN3+, and are most common in CIN2+ and CIN3+ cases. HPV-18, 33/58 and 52 constitute the intermediate risk range, and 45, 51, 35/39/68 and 56/59/66 have the lowest risk.

3 years

34

USA

prospective cohort study

167

The cytology in LSILs, patients with HPV-31, HPV-39, and HPV-52 infections had a high incidence of HSILs.

20–46 months

35

Korea

retrospective study

1102

HPV-31/33/35/45/52/58 genotypes are more likely to develop into HSIL or cervical cancer.

30 months

5

USA

prospective multicenter study

2807

When cytological examination results showed ASC-US or LSILs at baseline, HPV-16 had the highest risk of CIN2+, HPV-31, HPV-18, HPV-33/58, HPV-51, and HPV-52 were in the middle risk range, and HPV-35/39/68, HPV-45, and HPV-56/59/66 had the lowest risk of CIN2+.

3 years

36

China

retrospective study

902

Women with cytological LSIL combined with HR-HPV-16/18/31/33/52/58 positive results should be recommended for colposcopy.

3 years

37

Denmark

prospective cohort study

8656

The risk associated with HPV-16 was the highest to develop into CIN3+, followed by HPV-18, HPV-33, and HPV-31.

12 years

38

Turkey

retrospective study

179

HPV-31 has the highest risk of developing CIN2+ among non-16/18 HPV genotypes.

2 years

39

Thailand

cross-sectional study

5433

The detection rate of HSIL ​+ ​could be increased by adding HPV-52/58 or HPV-31/52/58 genotyping to HPV-16/18 genotyping.

7 months

40

China

cross-sectional study

3997

HPV-16/18/33/52/58 showed a high sensitivity and specificity in detecting CIN2+ in ASCUS patients.

2 months

41

China

prospective observational study

19207

HPV-16/18/31/33/52/58 genotype positive patients have a high risk of CIN2+.

3 years

42

Japan

prospective cohort study

570

Women with cytological LSIL and histological CIN1-2 lesions, the cumulative probability of developing CIN 3 within 5 years was 20.5% for HPV16, 18, 31, 33, 35, 52, and 58.

39.1 months